Home
Subscription
December 2024 issue
November 2024 issue
October 2024 issue
September 2024 issue
August 2024 issue
July 2024 issue
June 2024 issue
May 2024 issue
April 2024 issue
April 1, 2024 issue
March 2024 issue
February 2024 issue
January 2024 issue
BACK ISSUES
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
|
Each issue will include an editorial on a topic that is important for the profession of pharmacy, as well as a review of a new drug that includes a comparison of the new drug with previously marketed drugs that are most similar in activity, and a New Drug Comparison Rating (NDCR) for the new drug. Read on for this month's issue.
December 2011 Issue
"I Never Told Her"
Anticipation
New therapeutic agents marketed in the United States in 2011
Index for Volume 6, 2011
Click Here to download PDF format
"I Never Told Her"
[To Top]
My mother, Anna Hussar, died in her sleep on Christmas morning
at the age of 97. Going to heaven was the best possible Christmas present she could have received. She was an extraordinary woman who had a strong faith and was committed to serve others. Although her physical activities were limited, she maintained an active "ministry" of encouraging others through her cards and phone calls. Even in her death she continued giving, having made a decision decades earlier to contribute her body for medical research. Her abilities and clarity of thinking were reflected by her playing her favorite game, Scrabble, until just three days before her death. She had lived in our home with my wife, Sue, and me since June, and we will continue to value that experience.
A hospice nurse responded promptly to our telephone call and confirmed my mother's death. Shortly thereafter, a funeral director arrived to take her body for the research program. Many weeks before, we had planned that our children and their families would celebrate Christmas at our home, and that they would be arriving mid-afternoon. Our son Eric, his wife Terra, and their four young children were the first to arrive. About 20 minutes after their arrival and our initial greetings, I realized that I had not seen our oldest grandchild, 5-year old Alex, since they first arrived. I asked his 4-year old brother Wesley if he knew where Alex was and he responded that Alex was sad that Nana died and was in her room. I went into her room and found Alex lying on her hospital bed. I tried to encourage him and, through tears, he responded, "Nana was a really good friend but I never told her."
I was struck by the sensitivity of this statement by a 5-year old. Even though I had known that my mother was in her final days, his comment made me realize that there were things that I should have told her, but had not. I have thought of my grandson's comment often with the realization that I have been too busy to take the time to provide the amount of love and encouragement that I should to my mother, other family members, and friends, particularly during times of need. I like to think that the activities that keep me so busy are of great importance and of value to others. But it takes a situation such as a death and the sensitivity of a 5-year old to make me realize that my rationalization is a weak excuse for failing to recognize the things that are most important.
I must do better in expressing appreciation to those whose love and friendship have been of value to me, and in providing encouragement and support for those I am in a position to help. If my mother had a concern about our family, it was that we were always very busy. It is ironic that her advice that I did not take seriously while she was living has captured my attention upon her death.
Daniel A. Hussar
Anticipation
[To Top]
With this issue we mark the completion of the sixth year of publication of The Pharmacist Activist. The index for this volume is at the bottom of this web page and all issues are available online (www.pharmacistactivist.com). NEWS-Line Publishing produces this newsletter at its cost, and I wish to express my personal appreciation to Jeff Zajac, John Buck, and Patrick Polli for their expertise in preparing the issues. I also wish to express my deep appreciation to the friend who has provided the financial support for The Pharmacist Activist because of his commitment to advance the profession of pharmacy through stimulation of discussion/debate on important issues and challenges.
The numerous thoughtful and informative communications from readers provides the motivation to continue with this initiative to address the issues that are of the greatest importance for the profession of pharmacy, as well as to provide objective and practical information regarding new drugs. I also appreciate the level of interest in the content of The Pharmacist Activist that has resulted in certain of the editorials being included in other publications and used in classroom discussions in some colleges of pharmacy. Some pharmacy organizations forward the publication to their members, and individual readers have forwarded copies to pharmacist colleagues and pharmacy students. The Pharmacist Activist continues to be available free-of-charge via email to any interested pharmacist or student pharmacist.
Best wishes for a healthy
and enjoyable new year!
Daniel A. Hussar
New therapeutic agents marketed in the United States in 2011
[To Top]
Click here to view New therapeutic agents marketed in the United States in 2011
Index for Volume 6, 2011
[To Top] January 2011 (No. 1)
A New Year, an Old Theme - Pharmacy Must Have a More Effective National Organizational Structure!
New Drug Review:
Fingolimod hydrochloride (Gilenya)
February 2011 (No. 2)
Priorities for our Profession
New Drug Review: Pegloticase (Krystexxa)
March 2011 (No. 3)
Both Patients and Health Care Have a Great Need for a Personal Touch!
New Drug Review:
Collagenase clostridium histolyticum (Xiaflex)
April 2011 (No. 4)
The Large Chains are Making a Mockery of our Profession - And our Profession is a Co-conspirator Through our Silence!
New Drug Review: Azilsartan medoxomil (Edarbi)
May 2011 (No. 5)
Mail-Order Pharmacy Programs - Limitations, Inequities, and Deception
New Drug Review: Ceftaroline fosamil (Teflaro)
June 2011 (No. 6)
Pharmacy's Vision for 2015 OR a Large Surplus of Pharmacists?
New Drug Review: Linagliptin (Tradjenta)
July 2011 (No. 7)
Express Scripts and Medco - A Fallen Giant or a Bigger Monster?
New Drug Review: Vilazodone hydrochloride (Viibryd)
August 2011 (No. 8)
Drug Shortages - Pharmaceutical Companies Have Caused This Problem and it is Their Responsibility to Resolve It!
New Drug Review: Lurasidone hydrochloride (Latuda)
September 2011 (No. 9)
The Tylenol Follies
New Drug Review: Rivaroxaban (Xarelto)
October 2011 (No. 10)
Deception and Hypocrisy from Mail-Order Pharmacies
New Drug Review: Ticagrelor (Brilinta)
November 2011 (No. 11)
Merchants of Death - Chain Pharmacy CEOs Must Stop the Sale of Cigarettes!
New Drug Review: Telaprevir (Incivek)
December 2011 (No. 12)
"I Never Told Her"
New Therapeutic Agents Marketed in the United States in 2011 (Table)
Index for 2011
|
|
[To Top]
| |